Page last updated: 2024-11-07

higenamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Higenamine is an alkaloid found in various plants, particularly in the genus Aconitum. It has garnered attention for its potential pharmacological properties, particularly in the realm of cardiovascular health. Studies suggest that higenamine may exhibit effects on heart rate, blood pressure, and vascular tone. Its mechanism of action is thought to involve interaction with ion channels and neurotransmitter systems. The compound has been investigated for its potential benefits in treating conditions such as arrhythmias, hypertension, and heart failure. However, research on higenamine is still in its early stages, and its clinical efficacy and safety remain to be fully established. Further research is necessary to explore its therapeutic potential and address any potential risks associated with its use.'

higenamine: structure; RN given refers to (+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114840
CHEMBL ID19344
CHEBI ID18418
SCHEMBL ID636788
MeSH IDM0059314

Synonyms (47)

Synonym
(+-)-norcoclaurine
(+-)-demethylcoclaurine
CHEBI:18418 ,
(rs)-norcoclaurine
(+-)-1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-6,7-isoquinolinediol
1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol
(+-)-o-demethylcoclaurine
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-, (+-)-
coclaurine, o-demethyl-, (+-)-
higenamine
6,7-dihydroxy-1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
5843-65-2
(r,s)-norcoclaurine
C06346
CHEMBL19344
dl-demethylcoclaurine
1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol
tbv5o16gap ,
unii-tbv5o16gap
S3294
AKOS023077522
SCHEMBL636788
higenamine [who-dd]
(+/-)-demethylcoclaurine
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-
isoquinolin-6,7-diol, 1,2,3,4-tetrahydro-1-[4-hydroxybenzyl]-
WZRCQWQRFZITDX-UHFFFAOYSA-N
1-(4-hydroxybenzyl)-1,2,3,4-tetrahydro-6,7-isoquinolinediol #
demethyl-coclaurine
AC-26394
(r)-higenamine
mfcd01736979
NCGC00408795-01
6,7-dihydroxy-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline
DB12779
CS-0018527
HY-N2037
Q5754240
EN300-822192
AMY36791
DTXSID70973974
1,2,3,4-tetrahydro-1-(4-hydroxybenzyl)isoquinoline-6,7-diol
(+/-)-higenamine - synthetic
XH164059
bdbm50594953
norcoclaurine;demethyl-coclaurine
FS-8108

Research Excerpts

Overview

Higenamine is an alkaloid found in aconite, Annona squamosa, nanzhu (sacred bamboo), and other plants. Higenamine has been included in the Prohibited List of the World Anti-Doping Agency (WADA) since 2017.

ExcerptReferenceRelevance
"Higenamine is a tetrahydroisoquinoline present in several plant species and has β2AR agonist activity, but the involvement of each functional groups in β2AR agonist activity and its effectiveness compared with endogenous catecholamines (dopamine, epinephrine, and norepinephrine) has rarely been studied."( Ability of higenamine and related compounds to enhance glucose uptake in L6 cells.
Kato, E; Kawabata, J; Kimura, S, 2017
)
1.57
"Higenamine is an alkaloid found in aconite, Annona squamosa, nanzhu (sacred bamboo), and other plants. "( Identification and characterization of higenamine metabolites in human urine by quadrupole-orbitrap LC-MS/MS for doping control.
Fei, Q; Lu, J; Luan, Z; Wang, X; Wei, H; Xu, Y; Yuan, Y; Zhao, X, 2022
)
2.43
"Higenamine is an alkaloid found within plant species including some that are used in traditional Asian and Chinese herbal medicines. "( Presence of higenamine in beetroot containing 'foodstuffs' and the implication for WADA-relevant anti-doping testing.
Beck, P; Brown, P; Heath, J; Leaney, AE; Mawson, DH; Midforth, E, 2023
)
2.73
"Higenamine (HG) is a β-adrenergic receptor agonist currently approved for clinical trials as a stress agent for myocardial infarction."( Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease.
Li, ZJ; Zhang, NN; Zhu, HB, 2022
)
2.89
"Higenamine is a β2-agonist that has been included in the Prohibited List of the World Anti-Doping Agency (WADA) since 2017. "( The risk of higenamine adverse analytical findings following oral administration of plumula nelumbinis capsules.
Gao, X; Luan, Z; Wang, R; Wang, X; Wang, Y; Wang, Z; Yan, K, 2019
)
2.34
"Higenamine (HG) is a natural benzylisoquinoline alkaloid isolated from Aconitum with positive inotropic and chronotropic effects. "( Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function.
Li, H; Li, R; Liu, H; Wang, J; Wang, L; Wang, R; Wei, S; Wen, J; Zhang, L; Zhao, Y; Zou, W, 2020
)
2.31
"Higenamine (HG) is a plant-based alkaloid, possesses a wide range of activities, including vascular and tracheal relaxation, antioxidative, antiapoptotic, anti-inflammatory, and immunomodulatory activities."( Higenamine alleviates allergic rhinitis by activating AKT1 and suppressing the EGFR/JAK2/c-JUN signaling.
Deng, X; Liang, X; Liu, C; Tan, X; Wei, X; Xia, T; Xie, Y; Zhang, B, 2021
)
2.79
"Higenamine is a key component of traditional Chinese herbal medicine. "( Determination of higenamine and coclaurine levels in human urine after the administration of a throat lozenge containing Nandina domestica fruit.
Kageyama, S; Okano, M; Sato, M, 2017
)
2.24
"Higenamine is a tetrahydroisoquinoline present in several plants that has β-adrenergic receptor agonist activity. "( Synthesis and Detailed Examination of Spectral Properties of (S) and (R)-Higenamine 4'-O-β-d-Glucoside and HPLC Analytical Conditions to Distinguish the Diastereomers.
Iwata, R; Kato, E; Kawabata, J, 2017
)
2.13
"Higenamine is a stimulant with cardiovascular properties recently prohibited in sport by the World Anti-Doping Agency (WADA). "( The stimulant higenamine in weight loss and sports supplements.
Boyer, FE; Cohen, PA; Keizers, PHJ; Travis, JC; Venhuis, BJ, 2019
)
2.32
"Higenamine (HG) is an active compound derived from Aconiti root with a cardiotonic effect. "( The cardiac electrophysiology effects of higenamine in guinea pig heart.
Geng, J; Han, Y; Jiang, J; Jiang, M; Li, C; Wang, Y, 2019
)
2.22
"Higenamine (HG) is a well-known selective activator of beta2-adrenergic receptor (β2-AR) with a positive inotropic effect. "( Protective effects of higenamine combined with [6]-gingerol against doxorubicin-induced mitochondrial dysfunction and toxicity in H9c2 cells and potential mechanisms.
Cai, H; Li, H; Li, P; Wang, J; Wang, R; Wei, S; Wen, J; Zhang, L; Zhao, Y; Zhou, X, 2019
)
2.27
"Higenamine is a key component of the Chinese herb aconite root that has been prescribed for treating symptoms of heart failure for thousands of years in the oriental Asian countries."( Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway.
Dong, YR; Wu, MP; Xiong, J; Yan, C; Zhang, YS; Zhou, QM, 2016
)
2.6
"Higenamine is an active ingredient of Aconite root in Chinese herbal medicine and might be used as a new agent for a pharmaceutical stress test and was approved to undergo clinical pharmacokinetic study. "( Determination of higenamine in human plasma and urine using liquid chromatography coupled to positive electrospray ionization tandem mass spectrometry.
Feng, S; Hu, P; Jiang, J, 2011
)
2.15
"Higenamine (HG) is a potent cardioactive benzylisoquinoline alkaloid isolated from Aconiti tuber which has long been used as a cardiotonic in traditional Chinese medicine. "( [Effects of higenamine on the cardio-circulatory system].
Du, GY; Zhou, SJ, 2003
)
2.14

Effects

Higenamine (HI) has been shown to improve cardiac function in rats with heart failure. Higenamine also has ameliorative effects in the LPS-induced DIC model.

ExcerptReferenceRelevance
"Higenamine (HG) has anti-inflammatory, antioxidant and anti-apoptotic activities."( Higenamine improves DSS-induced ulcerative colitis in mice through the Galectin-3/TLR4/NF-κB pathway.
Hu, Y; Jiang, Y; Shao, XX; Xiao, HY; Xu, Y, 2023
)
3.07
"Higenamine (HI) has been shown to improve cardiac function in rats with heart failure."( Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
Deng, T; Deng, X; Fu, Q; Gael, A; Hang, L; Lai, J; Li, Z; Liu, Y; Wei, Z; Yan, Q, 2020
)
2.72
"Higenamine has desirable pharmacokinetic and pharmacodynamic characteristics. "( A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects.
Feng, S; Hu, P; Jiang, J; Li, BL; Liu, T; Zhang, JY; Zhao, Q, 2012
)
2.06
"Higenamine also has ameliorative effects in the LPS-induced DIC model."( [Effects of higenamine on the cardio-circulatory system].
Du, GY; Zhou, SJ, 2003
)
1.42

Actions

ExcerptReferenceRelevance
"Higenamine promotes cell apoptosis, inhibits colony formation, but does not inhibit proliferation of leukemia cells significantly."( Discovery of higenamine as a potent, selective and cellular active natural LSD1 inhibitor for MLL-rearranged leukemia therapy.
Fang, Y; Liao, G; Liu, Z; Luo, X; Su, S; Teng, D; Yang, C, 2021
)
1.71

Treatment

Higenamine treatment decreased serum creatinine (Scr), blood urea nitrogen, and brain natriuretic peptide levels. The treatment of higenamine weakened the harm of STZ on the number and morphology of gastric SMCs.

ExcerptReferenceRelevance
"Higenamine treatment decreased serum creatinine (Scr), blood urea nitrogen, and brain natriuretic peptide levels and was capable of improving left ventricular remodeling and systolic function in CRS rats, accompanied with decreased expression of transforming growth factor-β1 (TGF-β1), α-smooth muscle actin (α-SMA) and collagen I (Col1A1)."( Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
Deng, T; Deng, X; Fu, Q; Gael, A; Hang, L; Lai, J; Li, Z; Liu, Y; Wei, Z; Yan, Q, 2020
)
2.72
"The treatment of higenamine weakened the harm of STZ on the number and morphology of gastric SMCs."( Higenamine inhibits apoptosis and maintains survival of gastric smooth muscle cells in diabetic gastroparesis rat model via activating the β2-AR/PI3K/AKT pathway.
An, X; Chen, L; Deng, X; Long, C; Tang, A; Wang, Z; Xie, J, 2017
)
2.23

Toxicity

ExcerptReferenceRelevance
"HG can be used in pharmacological stress test with remarkable tolerability and safety even at the dosage of 500 microgram/kg/min without serious adverse effect."( [Effects of higeramine on hemodynamics and its tolerability and safety, an experimental study].
Chen, B; Liu, X; Liu, Y; Shi, R; Tao, Z; Yao, Z; Zhang, X; Zhang, Z; Zhu, K, 2002
)
0.31

Pharmacokinetics

Higenamine has desirable pharmacokinetic and pharmacodynamic characteristics. Plasma higenamine concentration declined rapidly in a biexponential pattern, with a terminal half-life of 22 min.

ExcerptReferenceRelevance
" Plasma higenamine concentration declined rapidly in a biexponential pattern, with a terminal half-life of 22 min."( Pharmacokinetics of higenamine in rabbits.
Chen, CM; Lo, CF, 1996
)
1.05
"Higenamine has desirable pharmacokinetic and pharmacodynamic characteristics."( A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects.
Feng, S; Hu, P; Jiang, J; Li, BL; Liu, T; Zhang, JY; Zhao, Q, 2012
)
2.06

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present study showed that HG combined with [6]-gingerol (HG/[6]-GR) protects H9c2 cells from doxorubicin (DOX)-induced mitochondrial energy metabolism disorder and respiratory dysfunction."( Protective effects of higenamine combined with [6]-gingerol against doxorubicin-induced mitochondrial dysfunction and toxicity in H9c2 cells and potential mechanisms.
Cai, H; Li, H; Li, P; Wang, J; Wang, R; Wei, S; Wen, J; Zhang, L; Zhao, Y; Zhou, X, 2019
)
0.83
" This study aimed to investigate the possible cardioprotective effects of HG combined with [6]-gingerol (HG/[6]-GR) against DOX-induced chronic heart failure (CHF) by comprehensive approaches."( Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function.
Li, H; Li, R; Liu, H; Wang, J; Wang, L; Wang, R; Wei, S; Wen, J; Zhang, L; Zhao, Y; Zou, W, 2020
)
0.87

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"HG can be used in pharmacological stress test with remarkable tolerability and safety even at the dosage of 500 microgram/kg/min without serious adverse effect."( [Effects of higeramine on hemodynamics and its tolerability and safety, an experimental study].
Chen, B; Liu, X; Liu, Y; Shi, R; Tao, Z; Yao, Z; Zhang, X; Zhang, Z; Zhu, K, 2002
)
0.31
" Atenolol inhibited the increase in HR at a small dosage of higenamine but potentiated it at a higher dosage."( Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats.
Andersen, RJ; Jansakul, C; Mulvany, MJ; Praman, S; Williams, DE, 2012
)
0.62
" At the dosage used in this study, the maximum concentration of HG in some urine samples exceeded the WADA limit of 10."( Use of liquid chromatography-tandem mass spectrometry for determination of higenamine in urine following oral administration of traditional Chinese medicine.
Chi, M; Guo, C; Liu, D; Zhang, J; Zhang, N; Zhang, X, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
norcoclaurineA benzylisoquinoline alkaloid based on a benzyltetrahydroisoquinoline skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency30.11160.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)1.47000.00312.16029.6000AID1872428
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1872428Inhibition of full-length recombinant KDM1A (unknown origin) expressed in Escherichia coli BL21 DE using H3K4Me2 peptide as substrate incubated for 0.5 hrs by Amplex red assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1366659Agonist activity at beta2 adrenergic receptor in rat L6 cell lysate assessed as increase in intracellular 2-deoxyglucose uptake at 10 to 100 uM preincubated for 4 hrs followed by 2-deoxyglucose measured after 20 mins by fluorescence-based enzymatic assay 2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ability of higenamine and related compounds to enhance glucose uptake in L6 cells.
AID1872436Inhibition of recombinant MAO-B (unknown origin) using luciferin substrate at 10 uM preincubated for 15 mins followed by substrate addition measured after 1 hr by luciferase based assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1872427Inhibition of recombinant MAO-A (unknown origin) using luciferin substrate at 10 uM preincubated for 15 mins followed by substrate addition measured after 1 hr by luciferase based assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1366654Agonist activity at beta2 adrenergic receptor in rat L6 cell lysate assessed as increase in intracellular 2-deoxyglucose uptake at more than 5 uM preincubated for 4 hrs followed by 2-deoxyglucose measured after 20 mins by fluorescence-based enzymatic assa2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ability of higenamine and related compounds to enhance glucose uptake in L6 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (20.30)18.7374
1990's14 (10.53)18.2507
2000's21 (15.79)29.6817
2010's42 (31.58)24.3611
2020's29 (21.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.06 (24.57)
Research Supply Index4.95 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index76.07 (26.88)
Search Engine Supply Index3.02 (0.95)

This Compound (36.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.94%)5.53%
Reviews9 (6.62%)6.00%
Case Studies1 (0.74%)4.05%
Observational0 (0.00%)0.25%
Other122 (89.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label, Single-dose Administration Study of the Pharmacokinetics and Pharmacodynamics of Higenamine, Administered Intravenously Injection to Healthy Chinese Subjects [NCT01451229]Phase 110 participants (Actual)Interventional2009-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]